Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DYRK1A | Q13627 | 3/20 | 0.42 |
| ▸ | HTR1B | P28222 | 5/20 | 0.33 |
| ▸ | HTR2A | P28223 | 1/20 | 0.32 |
| ▸ | HTR2C | P28335 | 1/20 | 0.32 |
| ▸ | CDK9 | P50750 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16471464 | 0.73 | HTR1B (0.34) | HTR1B | |
| SCHEMBL13677496 | 0.73 | NOS3 (0.34) | — | |
| SCHEMBL8312831 | 0.72 | DYRK1A (0.46) | DYRK1ACDK9 | |
| SCHEMBL31507530 | 0.72 | DYRK1A (0.46) | DYRK1ACDK9 | |
| SCHEMBL17844802 | 0.72 | DYRK1A (0.46) | DYRK1ACDK9 | |
| SCHEMBL18211805 | 0.72 | DYRK1A (0.39) | DYRK1AHTR1BHTR2AHTR2C | |
| SCHEMBL21477622 | 0.71 | GRM5 (0.30) | — | |
| SCHEMBL18238971 | 0.71 | DYRK1A (0.31) | DYRK1A | |
| SCHEMBL12269141 | 0.71 | NPC1 (0.41) | HTR2AHTR2C | |
| SCHEMBL24174483 | 0.71 | DYRK1A (0.38) | DYRK1AHTR1BCDK9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240207273-A1 | TREATMENT OF AUTISM SPECTRUM DISORDERS, OBSESSIVE-COMPULSIVE DISORDER AND ANXIETY DISORDERS | RUGEN HOLDINGS (CAYMAN) LIMITED (KY) | 2024-06-27 | — | — | US | disclosed |
| US-20230295167-A1 | POTENT AND SELECTIVE INHIBITORS OF HER2 | DANA-FARBER CANCER INSTITUTE, INC. | 2023-09-21 | — | — | US | disclosed |
| US-20230183237-A1 | COMPETITIVE AND NONCOMPETITIVE INHIBITORS OF THE MUSCARINIC ACETYLCHOLINE RECEPTOR M5 | VANDERBILT UNIVERSITY | 2023-06-15 | — | — | US | disclosed |
| US-20230183237-A1 | COMPETITIVE AND NONCOMPETITIVE INHIBITORS OF THE MUSCARINIC ACETYLCHOLINE RECEPTOR M5 | VANDERBILT UNIVERSITY | 2023-06-15 | — | — | US | disclosed |
| US-20210252011-A1 | TREATMENT OF GLIOBLASTOMA WITH FASN INHIBITORS | CORNELL UNIVERSITY | 2021-08-19 | — | — | US | disclosed |
| US-11091462-B2 | (Hetero)arylamide compound for inhibiting protein kinase activity | SHENZHEN TARGETRX, INC. (CN) | 2021-08-17 | — | — | US | disclosed |
| EP-3838897-A2 | (HETERO)ARYLAMIDE COMPOUND FOR INHIBITING PROTEIN KINASE ACTIVITY | Shenzhen TargetRx, Inc. (CN) | 2021-06-23 | — | — | EP | disclosed |
| EP-3553056-B1 | (HETERO)ARYLAMIDE COMPOUND FOR INHIBITING PROTEIN KINASE ACTIVITY | SHENZHEN TARGETRX INC (CN) | 2021-02-17 | — | — | EP | disclosed |
| US-20200377473-A9 | (HETERO)ARYLAMIDE COMPOUND FOR INHIBITING PROTEIN KINASE ACTIVITY | SHENZHEN TARGETRX, INC. (CN) | 2020-12-03 | — | — | US | disclosed |
| US-10457655-B2 | Compounds and compositions for inhibition of FASN | FORMA THERAPEUTICS, INC. (US) | 2019-10-29 | — | — | US | disclosed |
| US-9670196-B2 | Thiazole-substituted aminoheteroaryls as Spleen Tyrosine Kinase inhibitors | MERCK SHARP & DOHME CORP. (US) | 2017-06-06 | — | — | US | disclosed |
| US-20160326156-A1 | THIAZOLE-SUBSTITUTED AMINOHETEROARYLS AS SPLEEN TYROSINE KINASE INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2016-11-10 | — | — | US | disclosed |
| US-20160145220-A1 | NITROGEN-CONTAINING SATURATED HETEROCYCLIC COMPOUND | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2016-05-26 | — | — | US | disclosed |
| US-9278944-B2 | Nitrogen-containing saturated heterocyclic compound | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2016-03-08 | — | — | US | disclosed |
| US-20140011807-A1 | NITROGEN-CONTAINING SATURATED HETEROCYCLIC COMPOUND | SHANGHAI PHARMACEUTICALS HOLDING CO., LTD. (CN) | 2014-01-09 | — | — | US | disclosed |
| US-8058289-B2 | Pyridine methylene azolidinones and use thereof phosphoinositide inhibitors | MERCK SERONO SA (CH) | 2011-11-15 | — | — | US | disclosed |
| WO-2011138657-A1 | ARYL SUBSTITUTED OLEFINIC COMPOUNDS AS PDE10A INHIBITORS | GLENMARK PHARMACEUTICALS S.A. (CH) | 2011-11-10 | — | — | WO | disclosed |
| US-20110034458-A1 | PYRIDINE METHYLENE AZOLIDINONES AND USE THEREOF PHOSPHOINOSITIDE INHIBITORS | APPLIED RESEARCH SYSTEMS ARS HOLDING N.V. (AN) | 2011-02-10 | — | — | US | disclosed |
| US-7842698-B2 | Pyridine methylene azolidinones and use thereof phosphoinositide inhibitors | MERCK SERONO S.A. (CH) | 2010-11-30 | — | — | US | disclosed |
| US-20080269227-A1 | Pyridine Methylene Azolidinones and Use Thereof Phosphoinositide Inhibitors | APPLIED RESEARCH SYSTEM ARS HOLDING N.V. (NL) | 2008-10-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080269227-A1 | Pyridine Methylene Azolidinones and Use Thereof Phosphoinositide Inhibitors | PIK3CD, PIK3CA, PIK3CB | DYRK1A 3122/4885HTR1B 1667/4885HTR2A 3238/4885 |
| US-11091462-B2 | (Hetero)arylamide compound for inhibiting protein kinase activity | MAP2K2, MAP2K5, MAP2K4 | DYRK1A 138/4885HTR1B 2752/4885HTR2A 1888/4885 |
| US-20140011807-A1 | NITROGEN-CONTAINING SATURATED HETEROCYCLIC COMPOUND | REN, AGTR1, AGTR2 | DYRK1A 3955/4885HTR1B 888/4885HTR2A 1242/4885 |
| US-20230183237-A1 | COMPETITIVE AND NONCOMPETITIVE INHIBITORS OF THE MUSCARINIC ACETYLCHOLINE RECEPTOR M5 | CHRM5, CHRM1, CHRM2 | DYRK1A 1086/4885HTR1B 49/4885HTR2A 65/4885 |
| US-20230295167-A1 | POTENT AND SELECTIVE INHIBITORS OF HER2 | ERBB2, EGFR, ERBB3 | DYRK1A 43/4885HTR1B 587/4885HTR2A 594/4885 |
| US-20200377473-A9 | (HETERO)ARYLAMIDE COMPOUND FOR INHIBITING PROTEIN KINASE ACTIVITY | MAP2K2, MAP2K4, MAP2K5 | DYRK1A 135/4885HTR1B 2703/4885HTR2A 1871/4885 |
| US-20210252011-A1 | TREATMENT OF GLIOBLASTOMA WITH FASN INHIBITORS | AIFM2, FABP7, FASN | DYRK1A 4293/4885HTR1B 4079/4885HTR2A 3874/4885 |
| US-20160326156-A1 | THIAZOLE-SUBSTITUTED AMINOHETEROARYLS AS SPLEEN TYROSINE KINASE INHIBITORS | SYK, BTK, TYRO3 | DYRK1A 77/4885HTR1B 2184/4885HTR2A 2526/4885 |
| US-20160145220-A1 | NITROGEN-CONTAINING SATURATED HETEROCYCLIC COMPOUND | REN, AGTR1, AGTR2 | DYRK1A 3955/4885HTR1B 888/4885HTR2A 1242/4885 |
| US-20110034458-A1 | PYRIDINE METHYLENE AZOLIDINONES AND USE THEREOF PHOSPHOINOSITIDE INHIBITORS | PIK3CD, PIK3CA, PTEN | DYRK1A 3298/4885HTR1B 1544/4885HTR2A 3152/4885 |
| US-20240207273-A1 | TREATMENT OF AUTISM SPECTRUM DISORDERS, OBSESSIVE-COMPULSIVE DISORDER AND ANXIETY DISORDERS | GRIN2A, GRIN1, GRIN2B | DYRK1A 2871/4885HTR1B 91/4885HTR2A 77/4885 |
| US-10457655-B2 | Compounds and compositions for inhibition of FASN | FASN, FABP1, SCD | DYRK1A 4872/4885HTR1B 1345/4885HTR2A 2888/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.